MICROPORT (00853) announced its 2025 annual results, reporting revenue of approximately $1.105 billion, a year-on-year increase of 6%. Profit attributable to equity shareholders was $48.519 million, turning a loss into a profit compared to the same period last year. Basic earnings per share were 2.59 US cents. Operating cash flow also turned positive, reaching $69.1 million.
The company stated that the revenue growth was primarily driven by rapid market penetration and contributions from new products. During the reporting period, the group's "Global Access" commercialization platform made significant progress, driving a 78.8% year-on-year increase (excluding foreign exchange impact) in related business revenue to $163.9 million, achieving a break-even point within the period. Notably, overseas sales for core businesses such as surgical robots and structural heart products expanded by 286.6% and 255.0% year-on-year respectively (excluding foreign exchange impact). The platform's revenue sources are becoming increasingly diversified, and business synergies continue to strengthen, establishing it as a core engine for the group's growth.
As the group's first core product line to undergo national volume-based procurement, the cardiovascular intervention business has successfully navigated industry cycles through its strategic transformation towards a "Comprehensive Coronary Artery Disease Solution." It has maintained an adjusted net profit margin exceeding 20% for two consecutive years, demonstrating robust and healthy performance that validates its sustainable business model and operational resilience.
During the reporting period, the group systematically covered the entire innovation chain from "frontier exploration—regulatory breakthroughs—product commercialization—high-level evidence generation." In exploration and registration, eight new products entered the national green channel for innovative medical devices, bringing the cumulative total to 44 products, maintaining the leading industry position for the eleventh consecutive year. Two products received the "Breakthrough Device" designation from the US FDA. On the product and evidence generation front, several key products were approved for launch globally. Furthermore, the full clinical study of the self-developed Firehawk® coronary stent was published in The New England Journal of Medicine (NEJM), signifying international top-tier academic recognition of its R&D capabilities and laying a solid foundation for long-term development.
Within the reporting period, the group completed the strategic integration of its structural heart business and its cardiac rhythm management business. This integration not only optimized operational efficiency but also significantly improved the health of the group's financial statements. More strategically, through this integration, the group has strongly entered the high-value field of heart failure treatment, committed to building a global specialized medical device platform covering the entire "monitoring—diagnosis—treatment—management" process for heart failure, opening a promising new growth trajectory for the group.